Key Highlights

  • Eli Lilly’s experimental triple-receptor drug retatrutide achieved success in its first Phase 3 study involving Type 2 diabetes participants
  • HbA1c levels decreased by 1.7%–2% compared to 0.8% in the placebo group after 40 weeks
  • Body weight reduction reached 16.8% among participants receiving the maximum dose
  • The drug activates three hormone pathways (GLP-1, GIP, glucagon) compared to one or two pathways in currently available medications
  • Regulatory submission to the FDA remains pending; Lilly anticipates seven additional Phase 3 results before 2025 concludes

Eli Lilly reported Thursday that retatrutide, its investigational medication, successfully achieved the primary endpoint in its inaugural late-stage diabetes study, delivering meaningful blood sugar reductions alongside significant body weight decreases in Type 2 diabetes participants.

The 40-week study enrolled participants with Type 2 diabetes who were controlling their condition solely through lifestyle modifications—diet and exercise. Participants began the trial with HbA1c measurements falling between 7% and 9.5%.


LLY Stock Card
Eli Lilly and Company, LLY

Across various dosing levels, retatrutide produced average HbA1c decreases ranging from 1.7% to 2%, substantially outperforming the placebo group’s 0.8% reduction. These results satisfied the study’s primary objective.

Regarding body weight changes, participants receiving the maximum dose experienced an average weight reduction of 16.8% among those who completed treatment. The analysis including all enrolled participants—regardless of whether they discontinued—showed a 15.3% average decrease.

By comparison, Lilly’s currently marketed medication Zepbound produced weight reductions between 11% and 13.1% in similar 40-week diabetes studies. Retatrutide’s weight loss performance appears superior, though direct comparison trials have yet to be conducted.

Scotiabank analyst Louise Chen characterized the findings as “the highest levels of weight loss we’ve seen from an obesity drug to date” within a patient population known for facing particular challenges with weight reduction.

J.P. Morgan analysts provided a more balanced assessment, highlighting that the drug’s benefits must be weighed against elevated adverse event rates relative to Lilly’s diabetes medication Mounjaro.

Mechanism of Action Behind Retatrutide

Retatrutide functions as a weekly injection that stimulates three distinct hormone receptors—GLP-1, GIP, and glucagon—which has led to its “triple-G” designation. This represents one additional pathway beyond Zepbound (tirzepatide), which activates GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which activates GLP-1 alone.

The therapeutic rationale centers on simultaneously engaging all three biological pathways to reduce appetite, manage blood sugar levels, and enhance metabolic calorie expenditure.

Adverse reactions predominantly involved the gastrointestinal system. Approximately 26.5% of participants receiving the highest dose reported nausea, 22.8% experienced diarrhea, and 17.6% had vomiting episodes. Treatment discontinuation due to adverse effects occurred in up to 5% of participants, which Lilly characterized as comparatively modest.

A limited number of participants developed dysesthesia—an uncomfortable nerve-related sensation.

Regulatory Timeline and Next Steps

Lilly has yet to submit regulatory applications for retatrutide approval in either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 dataset released for this compound.

The pharmaceutical company anticipates receiving data from seven more Phase 3 studies prior to the end of 2025, encompassing diverse patient groups.

Lilly is simultaneously preparing for the second-quarter 2025 launch of its oral obesity medication orforglipron, contingent on FDA clearance.

Novo Nordisk, Lilly’s primary competitor, is pursuing its own advancement in this therapeutic area. During March 2025, Novo secured rights to a triple-receptor compound from United Laboratories International through a deal valued at up to $2 billion—though this candidate remains in early-stage development with commercial availability still years away.

Lilly shares (LLY) experienced modest declines in premarket trading Thursday following the announcement of these results.